These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 33234363)
1. Synergistic breast cancer suppression efficacy of doxorubicin by combination with glycyrrhetinic acid as an angiogenesis inhibitor. Shi J; Li J; Li J; Li R; Wu X; Gao F; Zou L; Mak WWS; Fu C; Zhang J; Leung GP Phytomedicine; 2021 Jan; 81():153408. PubMed ID: 33234363 [TBL] [Abstract][Full Text] [Related]
2. Oridonin synergistically enhances the anti-tumor efficacy of doxorubicin against aggressive breast cancer via pro-apoptotic and anti-angiogenic effects. Li J; Wu Y; Wang D; Zou L; Fu C; Zhang J; Leung GP Pharmacol Res; 2019 Aug; 146():104313. PubMed ID: 31202781 [TBL] [Abstract][Full Text] [Related]
3. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin. Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697 [TBL] [Abstract][Full Text] [Related]
4. Natural compound glycyrrhetinic acid protects against doxorubicin-induced cardiotoxicity by activating the Nrf2/HO-1 signaling pathway. Cheng Y; Wu X; Nie X; Wu Y; Zhang C; Lee SM; Lv K; Leung GP; Fu C; Zhang J; Li J Phytomedicine; 2022 Nov; 106():154407. PubMed ID: 36070662 [TBL] [Abstract][Full Text] [Related]
5. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models. Wu XY; Xu H; Wu ZF; Chen C; Liu JY; Wu GN; Yao XQ; Liu FK; Li G; Shen L Oncotarget; 2015 Dec; 6(42):44563-78. PubMed ID: 26575424 [TBL] [Abstract][Full Text] [Related]
6. Co-delivery of cisplatin and doxorubicin by covalently conjugating with polyamidoamine dendrimer for enhanced synergistic cancer therapy. Guo XL; Kang XX; Wang YQ; Zhang XJ; Li CJ; Liu Y; Du LB Acta Biomater; 2019 Jan; 84():367-377. PubMed ID: 30528609 [TBL] [Abstract][Full Text] [Related]
7. Glycyrrhetinic acid-conjugated polymeric prodrug micelles co-delivered with doxorubicin as combination therapy treatment for liver cancer. Yang T; Lan Y; Cao M; Ma X; Cao A; Sun Y; Yang J; Li L; Liu Y Colloids Surf B Biointerfaces; 2019 Mar; 175():106-115. PubMed ID: 30529816 [TBL] [Abstract][Full Text] [Related]
8. Liposomes co-encapsulating doxorubicin and glucoevatromonoside derivative induce synergic cytotoxic response against breast cancer cell lines. Novais MVM; Gomes ER; Miranda MC; Silva JO; Gomes DA; Braga FC; Pádua RM; Oliveira MC Biomed Pharmacother; 2021 Apr; 136():111123. PubMed ID: 33486211 [TBL] [Abstract][Full Text] [Related]
9. Metabolomic Identification of Anticancer Metabolites of Australian Propolis and Proteomic Elucidation of Its Synergistic Mechanisms with Doxorubicin in the MCF7 Cells. Alsherbiny MA; Bhuyan DJ; Radwan I; Chang D; Li CG Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360606 [TBL] [Abstract][Full Text] [Related]
10. Dietary compound glycyrrhetinic acid suppresses tumor angiogenesis and growth by modulating antiangiogenic and proapoptotic pathways in vitro and in vivo. Li J; Tang F; Li R; Chen Z; Lee SM; Fu C; Zhang J; Leung GP J Nutr Biochem; 2020 Mar; 77():108268. PubMed ID: 31830590 [TBL] [Abstract][Full Text] [Related]
11. Saikosaponin D potentiates the antineoplastic effects of doxorubicin in drug-resistant breast cancer through perturbing NQO1-mediated intracellular redox balance. Luo F; Yang J; Yang X; Mi J; Ye T; Li G; Xie Y Phytomedicine; 2024 Oct; 133():155945. PubMed ID: 39146878 [TBL] [Abstract][Full Text] [Related]
12. Multifunctional hybrid nanoconstructs facilitate intracellular localization of doxorubicin and genistein to enhance apoptotic and anti-angiogenic efficacy in breast adenocarcinoma. Shukla RP; Dewangan J; Urandur S; Banala VT; Diwedi M; Sharma S; Agrawal S; Rath SK; Trivedi R; Mishra PR Biomater Sci; 2020 Mar; 8(5):1298-1315. PubMed ID: 31903460 [TBL] [Abstract][Full Text] [Related]
13. GPR91 Receptor Mediates Protection against Doxorubicin-Induced Cardiotoxicity without Altering Its Anticancer Efficacy. An In Vitro Study on H9C2 Cardiomyoblasts and Breast Cancer-Derived MCF-7 Cells. Dallons M; Alpan E; Schepkens C; Tagliatti V; Colet JM Cells; 2020 Sep; 9(10):. PubMed ID: 32992522 [TBL] [Abstract][Full Text] [Related]
14. Selenadiazole Derivatives Inhibit Angiogenesis-Mediated Human Breast Tumor Growth by Suppressing the VEGFR2-Mediated ERK and AKT Signaling Pathways. Lai H; Fu X; Sang C; Hou L; Feng P; Li X; Chen T Chem Asian J; 2018 Jun; 13(11):1447-1457. PubMed ID: 29575811 [TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterase inhibitor, pentoxifylline enhances anticancer activity of histone deacetylase inhibitor, MS-275 in human breast cancer in vitro and in vivo. Nidhyanandan S; Boreddy TS; Chandrasekhar KB; Reddy ND; Kulkarni NM; Narayanan S Eur J Pharmacol; 2015 Oct; 764():508-519. PubMed ID: 26209365 [TBL] [Abstract][Full Text] [Related]
16. Synergistic Cytotoxicity of Renieramycin M and Doxorubicin in MCF-7 Breast Cancer Cells. Tun JO; Salvador-Reyes LA; Velarde MC; Saito N; Suwanborirux K; Concepcion GP Mar Drugs; 2019 Sep; 17(9):. PubMed ID: 31527453 [TBL] [Abstract][Full Text] [Related]
17. Dietary isoflavone daidzein synergizes centchroman action via induction of apoptosis and inhibition of PI3K/Akt pathway in MCF-7/MDA MB-231 human breast cancer cells. Kaushik S; Shyam H; Sharma R; Balapure AK Phytomedicine; 2018 Feb; 40():116-124. PubMed ID: 29496164 [TBL] [Abstract][Full Text] [Related]
18. Synergistic anti-cancer activity of the combination of dihydroartemisinin and doxorubicin in breast cancer cells. Wu GS; Lu JJ; Guo JJ; Huang MQ; Gan L; Chen XP; Wang YT Pharmacol Rep; 2013; 65(2):453-9. PubMed ID: 23744430 [TBL] [Abstract][Full Text] [Related]
19. Delivery of mitochondriotropic doxorubicin derivatives using self-assembling hyaluronic acid nanocarriers in doxorubicin-resistant breast cancer. Liu HN; Guo NN; Guo WW; Huang-Fu MY; Vakili MR; Chen JJ; Xu WH; Wei QC; Han M; Lavasanifar A; Gao JQ Acta Pharmacol Sin; 2018 Oct; 39(10):1681-1692. PubMed ID: 29849132 [TBL] [Abstract][Full Text] [Related]
20. Impact of ER520, a candidate of selective estrogen receptor modulators, on in vitro cell growth, migration, invasion, angiogenesis and in vivo tumor xenograft of human breast cancer cells. Wang L; Wang Y; Du H; Jiang Y; Tang Z; Liu H; Xiang H; Xiao H Cancer Chemother Pharmacol; 2015 Dec; 76(6):1247-57. PubMed ID: 26464351 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]